Department of Medicine
University of Wisconsin
BRAD S KAHL
Contact Information
1111 HIGHLAND AVE
MADISON, WI 53705
Biography
EDUCATION:1989 BS, University of Wisconsin-Madison, Madison, WI
1994 MD, Tufts University School of Medicine, Boston, MA
POST GRADUATE EDUCATION:
1994-1995 Intern; Internal Medicine, University of Wisconsin Hospital and Clinics
1995-1997 Resident; Internal Medicine, University of Wisconsin Hospital and Clinics
1997-1998 Chief Medical Resident; University of Wisconsin Hospital and Clinics
1998-2000 Hematology Fellow, University of Wisconsin Hospital and Clinics
Dr. Kahl is an Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. He is the Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies at the Paul P. Carbone Comprehensive Cancer Center. He received his medical degree from Tufts University where he was elected AOA. He completed all post-graduate training at the University of Wisconsin and was appointed to the faculty in 2000. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.
Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of E4402, Rituximab Extended Schedule or Retreatment Trial (RESORT) and E1405, A phase II study VcR-CVAD with maintenance rituximab for untreated Mantle Cell Lymphoma.
Search for Brad Kahl's literature abstracts on PubMed
Kahl B, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17:1418-1423.
Fisher RI, Bernstein SH, Kahl B, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer E, O'Connor O, Shi H, Boral A, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24;4867-4874.
Micallef IN, Kahl B, Mauer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Cancer 2006; 107:2826-32.
Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl B. A five-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007;25:87-93.
Robertson MJ, Kahl B, Vose J, de Vos S, Laughlin M, Flynn P, Rowland K, Cruz K, Goldberg S, Darstein C, Enas N, Neuberg D, Savage K, Lacasce A, Thornton D, Slapak CA, Shipp M. Phase II study of enzastaurin, a protein kinase C-β inhibitor, in patients with relapsed and refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-1746.